{"filings":[{"id":101611,"accession_number":"0001663577-26-000064","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.03","8.1"],"status":"ready","headline":"Bio-Path Holdings completes domestication to Wyoming, creates Series S Preferred stock","event_type":"other_material","confidence":"high","bullets":["Domestication to Wyoming approved March 5, 2026; state of incorporation changed from Delaware.","Created 51 authorized shares of Series S Preferred, each convertible into one common share with 1% diluted voting power.","Appointed Wendy M. Charles and Michael Hickey to Scientific Advisory Board effective Feb 10, 2026.","Each new advisor received 100,000 stock options at $0.06 exercise price, expiring in three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101610,"accession_number":"0001663577-26-000046","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.01","5.03","7.1","8.1"],"status":"ready","headline":"Bio-Path issues Series S preferred to CEO entity, giving 51% voting control; cancels reverse split, plans trial restarts","event_type":"other_material","confidence":"high","bullets":["Issued 51 Series S preferred shares (1% vote each) and 2M warrants to CEO-controlled SGA, granting 51% voting control.","$10K accrued payables used as consideration for the preferred and warrants; no new capital raised.","Filing to domesticate to Wyoming from Delaware; expected approval March 2026.","In talks with creditors to restructure; plans to restart Phase 1/2 trials for AML, solid tumors, and obesity.","Canceled previously approved 1-30 reverse split; created Strategic Advisory Board and reserved 1.5M incentive stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117959,"accession_number":"0001663577-25-000317","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Bio-Path warns of going concern doubt, seeks financing; director resigns","event_type":"other","confidence":"medium","bullets":["Director Douglas Morris resigned effective Nov 13, 2025; resignation received Nov 4.","Company seeking financing to fund turnaround; plans to update finance team, engage new PCAOB auditors, hire investment bankers to review biotech portfolio for sale/partnership/M&A.","Warns substantial doubt about ability to continue as going concern if capital raise fails; notes risk of delisting from OTC Markets.","No specifics on financing amount or timeline; strategic review of portfolio and M&A pursuits announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117958,"accession_number":"0001663577-25-000303","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bio-Path appoints Vikram Grover as CEO, CFO and director; Morris resigns as interim CEO/CFO","event_type":"leadership","confidence":"high","bullets":["Vikram Grover elected President, CEO, CFO and Board member effective October 22, 2025.","Douglas Morris resigned as Interim CEO and Interim CFO but remains on the Board.","Paul Aubert resigned as director, effective October 22, 2025.","Grover now holds both CEO and CFO roles, consolidating leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134411,"accession_number":"0001104659-25-077665","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Bio-Path Holdings dismisses EY as auditor; no disagreements; seeking replacement","event_type":"other_material","confidence":"high","bullets":["Board approved dismissal of EY as independent auditor on Aug 13, 2025, effective immediately.","EY's reports for FY 2024 and 2023 were unqualified except for a going concern explanatory paragraph.","No disagreements or reportable events with EY during the two most recent fiscal years or interim period.","Company is actively seeking a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151233,"accession_number":"0001558370-25-008814","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Bio-Path Holdings CEO and entire board resign; operations paused, employees furloughed","event_type":"other_material","confidence":"high","bullets":["CEO/President/CFO/Chairman Peter H. Nielsen resigned June 20, 2025, from all roles.","Board members Heath Cleaver and Aline Sherwood resigned June 20-21, 2025.","Douglas P. Morris appointed Chairman on June 22, 2025; no changes to his compensation.","Company instituted an operational pause, furloughed most employees, and is seeking financing.","Without financing, company may delay programs, dispose of assets, or liquidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}